Back to Search
Start Over
Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.
- Source :
- Diabetes Care; Feb2022, Vol. 45 Issue 2, pe27-e29, 3p
- Publication Year :
- 2022
-
Abstract
- The article presents the discussion on the effect of Dapagliflozin on Hematocrit in patients with type 2 diabetes at high cardiovascular risk. Topics include expanding beyond patients with type 2 diabetes (T2D) to patients with heart failure and chronic kidney disease regardless of T2D status; and evidence suggesting a relationship between SGLT2 inhibitors and increasing hematocrit (Hct) hemoglobiin.
Details
- Language :
- English
- ISSN :
- 01495992
- Volume :
- 45
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Diabetes Care
- Publication Type :
- Academic Journal
- Accession number :
- 154851061
- Full Text :
- https://doi.org/10.2337/dc21-1668